Abraxane/rituxan 160 complex
Abraxane/rituxan 160 complex - a formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the cd20 antigen found on b-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle ar160, the rituximab moiety specifically binds to cd20 and targets this formulation to cd20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the cd20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets cd20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity. Also see nab-paclitaxel/rituximab-coated nanoparticle ar160
Up to date info
Latest research - Abraxane/rituxan 160 complex
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Abraxane/rituxan 160 complex for any updates.